PDT Partners’s TG Therapeutics TGTX Stock Holding History

PDT Partners’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28M	Hold	41,585	–	–	0.12%	226
2026 Q1	$1.38M	Hold	41,585	–	–	0.08%	292
2025 Q4	$1.24M	Buy	41,585 +9,400	+29%	+$307K	0.08%	323
2025 Q3	$1.16M	Hold	32,185	–	–	0.07%	336
2025 Q2	$1.16M	Sell	32,185 -2	-0%	-$74	0.07%	399
2025 Q1	$1.27M	Hold	32,187	–	–	0.09%	348
2024 Q4	$969K	Sell	32,187 -28,482	-47%	-$817K	0.09%	347
2024 Q3	$1.42M	Buy	+60,669	New	+$1.33M	0.13%	296
2022 Q4	–	Sell	-58,466	Closed	-$346K	–	888
2022 Q3	$346K	Sell	58,466 -83,460	-59%	-$547K	0.05%	539
2022 Q2	$603K	Buy	+141,926	New	+$886K	0.05%	551
2020 Q1	–	Sell	-28,596	Closed	-$317K	–	851
2019 Q4	$317K	Buy	+28,596	New	+$217K	0.02%	524

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

PDT Partners's TGTX Position: Q2 2026 in Review

PDT Partners held its TG Therapeutics (TGTX) position steady in Q2 2026 at 41,585 shares worth $2.28M. The position accounts for 0.12% of the portfolio, ranked #226.

PDT Partners first reported a position in TGTX in Q4 2019 and has held it in 11 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

PDT Partners held 41,585 shares of TG Therapeutics worth $2.28M as of Q2 2026.
PDT Partners left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.12% of PDT Partners's portfolio in Q2 2026, its #226 holding.
PDT Partners first reported a position in TG Therapeutics in Q4 2019 and has held it in 11 quarters since.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.